Search Results

There are 9029 results for: content related to: Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial

  1. You have free access to this content
    Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

    HIV Medicine

    Volume 15, Issue 6, July 2014, Pages: 330–338, E Martinez, A Gonzalez-Cordon, E Ferrer, P Domingo, E Negredo, F Gutierrez, J Portilla, A Curran, D Podzamczer, J Murillas, JI Bernardino, I Santos, JA Carton, J Peraire, J Pich, I Perez, JM Gatell and for the ATADAR Study Group

    Version of Record online : 12 JAN 2014, DOI: 10.1111/hiv.12121

  2. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting

    HIV Medicine

    Volume 15, Issue 7, August 2014, Pages: 417–424, J Macías, E Recio, M Márquez, C García, P Jiménez, D Merino, L Muñoz, J Pasquau, G Ojeda, P Bancalero, N Chueca and JA Pineda

    Version of Record online : 24 FEB 2014, DOI: 10.1111/hiv.12129

  3. Pharmacokinetic Interactions Between Darunavir/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine/Naloxone

    The Journal of Clinical Pharmacology

    Volume 51, Issue 2, February 2011, Pages: 271–278, Dr Vanitha Sekar, Dr Frank Tomaka, Dr Eric Lefebvre, Dr Martine De Pauw, Dr Tony Vangeneugden, Dr Wim van den Brink and Dr Richard Hoetelmans

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010365558

  4. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens

    HIV Medicine

    D Armenia, D Di Carlo, G Maffongelli, V Borghi, C Alteri, F Forbici, A Bertoli, C Gori, M Giuliani, E Nicastri, M Zaccarelli, C Pinnetti, S Cicalini, G D'Offizi, F Ceccherini-Silberstein, C Mussini, A Antinori, M Andreoni, CF Perno and MM Santoro

    Version of Record online : 28 JUN 2016, DOI: 10.1111/hiv.12388

  5. You have free access to this content
    The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline

    HIV Medicine

    Volume 13, Issue 7, August 2012, Pages: 398–405, JR Arribas, N Clumeck, M Nelson, A Hill, Y van Delft and C Moecklinghoff

    Version of Record online : 13 MAR 2012, DOI: 10.1111/j.1468-1293.2012.00989.x

  6. You have free access to this content
    Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

    HIV Medicine

    Volume 14, Issue 1, January 2013, Pages: 49–59, C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, E Lathouwers, E Lefebvre, M Opsomer, T Van de Casteele and F Tomaka

    Version of Record online : 23 OCT 2012, DOI: 10.1111/j.1468-1293.2012.01060.x

  7. Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain

    Journal of Medical Virology

    Berta Pernas, Marta Grandal, Andrés Tabernilla, Purificación Cid, Sonia Pértega, Ángeles Castro-Iglesias, Álvaro Mena, Luis Margusino, José D. Pedreira and Eva Poveda

    Version of Record online : 6 JUN 2016, DOI: 10.1002/jmv.24585

  8. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data

    HIV Medicine

    Volume 16, Issue 5, May 2015, Pages: 297–306, J Vingerhoets, V Calvez, P Flandre, A-G Marcelin, F Ceccherini-Silberstein, C-F Perno, M Mercedes Santoro, R Bateson, M Nelson, A Cozzi-Lepri, J Grarup, J Lundgren, F Incardona, R Kaiser, A Sonnerborg, B Clotet, R Paredes, HF Günthard, B Ledergerber, A Hoogstoel, S Nijs, L Tambuyzer, L Lavreys, M Opsomer and on behalf of the Etravirine Cohort Study Group

    Version of Record online : 14 JAN 2015, DOI: 10.1111/hiv.12218

  9. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial

    HIV Medicine

    PM Girard, A Antinori, JR Arribas, D Ripamonti, C Bicer, B Netzle-Sveine, B Hadacek and C Moecklinghoff

    Version of Record online : 9 JUN 2016, DOI: 10.1111/hiv.12386

  10. You have full text access to this OnlineOpen article
    Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

    HIV Medicine

    A Bamford, A Turkova, H Lyall, C Foster, N Klein, D Bastiaans, D Burger, S Bernadi, K Butler, E Chiappini, P Clayden, M Della Negra, V Giacomet, C Giaquinto, D Gibb, L Galli, M Hainaut, M Koros, L Marques, E Nastouli, T Niehues, A Noguera-Julian, P Rojo, C Rudin, HJ Scherpbier, G Tudor-Williams, SB Welch and (PENTA Steering Committee)

    Version of Record online : 3 FEB 2015, DOI: 10.1111/hiv.12217

  11. You have free access to this content
    Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients

    British Journal of Clinical Pharmacology

    Volume 68, Issue 1, July 2009, Pages: 116–119, Vanitha Sekar, Eric Lefebvre, Kris Mariën, Martine De Pauw, Tony Vangeneugden, Anton Pozniak and Richard M. W. Hoetelmans

    Version of Record online : 5 MAY 2009, DOI: 10.1111/j.1365-2125.2009.03430.x

  12. Evaluation of Atazanavir and Darunavir Interactions with Lipids for Developing pH-Responsive Anti-HIV Drug Combination Nanoparticles

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 8, August 2014, Pages: 2520–2529, Jinghua Duan, Jennifer P. Freeling, Josefin Koehn, Cuiling Shu and Rodney J. Y. Ho

    Version of Record online : 19 JUN 2014, DOI: 10.1002/jps.24046

  13. You have free access to this content
    Thermodynamic and structural analysis of HIV protease resistance to darunavir – analysis of heavily mutated patient-derived HIV-1 proteases

    The FEBS Journal

    Volume 281, Issue 7, April 2014, Pages: 1834–1847, Milan Kožíšek, Martin Lepšík, Klára Grantz Šašková, Jiří Brynda, Jan Konvalinka and Pavlína Řezáčová

    Version of Record online : 28 FEB 2014, DOI: 10.1111/febs.12743

  14. Dried blood spot analysis of (+) and (−) darunavir enantiomers on immobilized amylose tris-(3, 5-dimethylphenylcarbamate) LC and its application to pharmacokinetics

    Biomedical Chromatography

    Volume 29, Issue 12, December 2015, Pages: 1878–1884, Nageswara Rao Ramisetti, Manikanta Swamy Arnipalli and Narendra Varma Nimmu

    Version of Record online : 16 JUN 2015, DOI: 10.1002/bmc.3510

  15. PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis

    HIV Medicine

    Volume 17, Issue 6, June 2016, Pages: 453–459, G Fätkenheuer, H Jessen, A Stoehr, N Jung, AB Jessen, T Kümmerle, M Berger, JR Bogner, CD Spinner, C Stephan, O Degen, R Vogelmann, P Spornraft-Ragaller, E Schnaitmann, B Jensen, A Ulmer, JM Kittner, G Härter, P Malfertheiner, J Rockstroh, G Knecht, S Scholten, T Harrer, WV Kern, B Salzberger, D Schürmann and B Ranneberg

    Version of Record online : 11 MAY 2016, DOI: 10.1111/hiv.12363

  16. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy

    Journal of Medical Virology

    Volume 85, Issue 5, May 2013, Pages: 755–759, Claudio Ucciferri, Katia Falasca, Francesca Vignale, Marta Di Nicola, Eligio Pizzigallo and Jacopo Vecchiet

    Version of Record online : 18 MAR 2013, DOI: 10.1002/jmv.23543

  17. You have free access to this content
    Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: Relevance to drug resistance

    Protein Science

    Volume 19, Issue 11, November 2010, Pages: 2055–2072, Jane M. Sayer, Johnson Agniswamy, Irene T. Weber and John M. Louis

    Version of Record online : 29 SEP 2010, DOI: 10.1002/pro.486

  18. Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients

    Antiviral Drugs: From Basic Discovery through Clinical Trials

    Marie-Pierre de Béthune, Vanitha Sekar, Sabrina Spinosa-Guzman, Marc Vanstockem, Sandra De Meyer, Piet Wigerinck, Eric Lefebvre, Pages: 31–45, 2011

    Published Online : 20 JUN 2011, DOI: 10.1002/9780470929353.ch3

  19. Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children

    HIV Medicine

    Volume 15, Issue 8, September 2014, Pages: 511–512, K Chokephaibulkit, S Rungmaitree, W Phongsamart, K Lappra, O Wittawatmongkol, N Kongstan and TR Cressey

    Version of Record online : 19 AUG 2014, DOI: 10.1111/hiv.12163

  20. The FDA Approved HIV-1 Protease Inhibitors for Treatment of HIV/AIDS

    Standard Article

    Burger's Medicinal Chemistry and Drug Discovery

    Arun K. Ghosh, David D. Anderson and Hiroaki Mitsuya

    Published Online : 27 AUG 2010, DOI: 10.1002/0471266949.bmc224